Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.
Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
• History of severe and unexpected reactions to fluoropyrimidine therapy,
• Hypersensitivity to capecitabine or to any of the excipients listed in section 6.1 or fluorouracil,
• Known complete dihydropyrimidine dehydrogenase (DPD) deficiency (see section 4.4),
• During pregnancy and lactation,
• In patients with severe leukopenia, neutropenia, or thrombocytopenia,
• In patients with severe hepatic impairment,
• In patients with severe renal impairment (creatinine clearance below 30 mL/min),
• Recent or concomitant treatment with brivudine (see section 4.4 and 4.5 for drug-drug
interaction),
• If contraindications exist to any of the medicinal products in the combination regimen, that
medicinal product should not be used.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 or
fluorouracil,
• History of severe and unexpected reactions to fluoropyrimidine therapy,
• Known complete dihydropyrimidine dehydrogenase (DPD) deficiency (see section 4.4),
• During pregnancy and lactation,
• In patients with severe leukopenia, neutropenia, or thrombocytopenia,
• In patients with severe hepatic impairment,
• In patients with severe renal impairment (creatinine clearance below 30 mL/min),
• Recent or concomitant treatment with brivudine (see section 4.4 and 4.5 for drug-drug
interaction),
• If contraindications exist to any of the medicinal products in the combination regimen, that
medicinal product should not be used.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
• History of severe and unexpected reactions to fluoropyrimidine therapy,
• Hypersensitivity to capecitabine or to any of the excipients listed in section 6.1 or fluorouracil,
• Known complete dihydropyrimidine dehydrogenase (DPD) deficiency (see section 4.4).During
pregnancy and lactation,
• In patients with severe leukopenia, neutropenia, or thrombocytopenia,
• In patients with severe hepatic impairment,
• In patients with severe renal impairment (creatinine clearance below 30 ml/min),
• Recent or concomitant treatment with brivudine (see section 4.4 and 4.5 for drug-drug
interaction),If contraindications exist to any of the medicinal products in the combination
regimen, that medicinal product should not be used.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Version 2025-05-05T15:07:00Z · SHA-256 31136a37a67bcc7d3d37a3db0a926c5402c9346bcaefe911a69ae0fa32bf9225 · Passage a531d710babd80ed970efae050b1f211932d64c354f430ae882f1365fb3d9990 · Zeichen 0–770 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.